

second type is that of mild toxic encephalopathy that includes features of mood disorder together with impaired cognitive function. Sleep disorders and memory impairments are common. The third type, chronic dementia, represents the least common and advanced form of CNS effects. The prognosis of type 1 is excellent. Workers recover fully if they are removed from the excessive solvent exposure. The prognosis of type 2 would depend on its severity. At the early type 2, recovery is complete. However, if worker is removed from exposure at the late type 2, recovery may not be complete. The third type of the disease is not reversible. One would still recommend removal from solvent exposure as this will prevent the further deterioration of the disease⁽⁴⁾. Making a diagnosis of solvent encephalopathy is not difficult but it entails having considered the possibility. It has been said; "What you do not consider, you probably will miss." If you do see a patient with complaints of symptoms that are non-specific, consider the possibility of solvent related illness. Ask for possible exposure to solvents. If need be, the patient could be referred for further assessment. There are investigative tools that are available to assess the different aspect of behavioural functions.

REFERENCES

1. Chia SE, Chong PN, Neurological Disorders. Textbook of Occupational Practice. Jeyaratnam J, Koh D. World Scientific 1996: 159-188.
2. Republic of Singapore Government Gazette. The Factories (Medical Examinations) Regulations. Government Printer, Singapore 1997.
3. Iregren A. Behavioural methods and organic solvents: questions and consequences. Environ Health Perspect 1996;104 (Suppl 2):361-6.
4. Johnson BL. Prevention of Neurotoxic illness in working populations. New York: John Wiley & Sons, 1987.

Department of Community, Occupational and Family Medicine, National University of Singapore,
Lower Kent Ridge Road, Singapore 119260
S E Chia, MBBS, MSc (Occ Med), FAMS, MD, Senior Lecturer

Glaxo Wellcome plc

IMPORTANT NOTIFICATION RELATING TO INTELLECTUAL PROPERTY PROTECTION ON RANITIDINE AND RANITIDINE HYDROCHLORIDE

Glaxo Wellcome's ranitidine products for the treatment of ulcers and other gastrointestinal disorders are sold in Singapore by Glaxo Wellcome Singapore Pte Ltd under the registered trademark

ZANTAC

These products continue to be an important part of Glaxo Wellcome's portfolio of healthcare products in Singapore and elsewhere.

The specific polymorphic form of ranitidine hydrochloride known as Form 2, which is the active constituent in Zantac™ products, is the subject of Singapore Patent Registration No. 522/85, which remains in force until 1 October 2001.

Glaxo Wellcome also holds patents and other intellectual property rights in Singapore relating, inter alia, to processes for making ranitidine hydrochloride and certain intermediates, and to specific formulations and presentations, all of which remain in force until at least 2003.

It has come to the attention of Glaxo Wellcome that certain parties in Singapore have been involved in importing, offering for sale, selling and distributing "Urantac" 150mg tablets which are not manufactured by or with the consent of Glaxo Wellcome, and which contain Form 2 ranitidine hydrochloride, which is protected by the aforementioned Singapore Patent Registration No. 522/85.

Consumers and members of the public are advised that all genuine Glaxo Wellcome products are sold in Singapore under the Zantac trademark by Glaxo Wellcome's Sole Distributor, Inchcape Healthcare. Purchases of such products should only be made from the Sole Distributor or from authorised dealers appointed by the Sole Distributor.

TAKE NOTICE that Glaxo Wellcome will vigorously enforce its intellectual property rights in respect of ranitidine and ranitidine hydrochloride by commencing legal proceedings and seeking remedies including injunctions, delivery up of infringing products, damages and legal costs, as well as commencing criminal prosecution if necessary, in the event of infringement by authorised development sale, offer for sale, manufacture, importation, or stock-piling of ranitidine hydrochloride.